Parallax Volatility Advisers
NWBO

Parallax Volatility Advisers’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Parallax Volatility Advisers’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-25,960
Closed -$162K – 4690
2015
Q3 		$162K Buy
+25,960
New +$243K ﹤0.01% 1869

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's NWBO Position: Q4 2015 in Review

Parallax Volatility Advisers sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2015, closing a stake of 25,960 shares — an estimated $162K sold.

Parallax Volatility Advisers first reported a position in NWBO in Q3 2015 and held it in 1 quarter. The position peaked at $162K in Q3 2015. 80 funds tracked by Wall St. Rank hold NWBO as of Q4 2015.

  • Parallax Volatility Advisers reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2015 after selling out during the quarter.
  • Parallax Volatility Advisers sold 25,960 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2015, an estimated $162K.
  • Parallax Volatility Advisers first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2015 and held it in 1 quarter.
  • Parallax Volatility Advisers's Northwest Biotherapeutics, Inc. Common stock position peaked at $162K in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2015.

Based on Parallax Volatility Advisers's 13F filing for Q4 2015, filed 16 Feb 2016.